Amgen (AMGN) closed at $303.17 in the latest trading session, marking a +0.82% move from the prior day. This move outpaced the S&P 500's daily loss of 0.34%. Elsewhere, the Dow gained 0.03%, while the tech-heavy Nasdaq lost 0.56%.Shares of the world's largest biotech drugmaker witnessed a gain of 11.64% over the previous month, beating the performance of the Medical sector with its gain of 5.72% and the S&P 500's gain of 2.56%.The upcoming earnings release of Amgen will be of great interest to investors. Th ...

Firn Foreword While two-thirds of this collection of Dow Industrials (DJI) is too pricey and reveals only skinny dividends, two of the five lowest-priced Dogs of the Dow are ready to buy. This month, Verizon Communications Inc. (VZ), and Walgreens Boots Alliance (WBA) live up to the dogcatcher ideal of annual dividends from $1K invested exceeding their single share prices. However, six more, Dow Inc. (DOW), Cisco Systems (CSCO), Coca-Cola Co (KO), 3M Co (MMM), Chevron (CVX), and International Business Machi ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Generate:Biomedicines today announced key advancements across its clinical pipeline and generative AI platform, including its first patient dosed in GB-0895, progress in the phase 1 study for GB-0669, and an expansion of its collaboration agreement with Amgen. Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company’s strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Morgan Healthca ...

It’s a new year and apparently there’s a new theme on Wall Street for investors. Many of the Magnificent Seven stocks and their high-flying tech peers are off to a difficult start in 2024. But stodgy, dividend-paying consumer staples, telecom, and healthcare stocks are surging.Coca-Cola (NYSE:KO) was in the green on Tuesday and Wednesday while the broader market fell both days. Coke, a Dow Jones stock, is already up 2% after tumbling about 5% in 2023, missing the big market rally. The soft drink giant, whic ...

About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this world's largest biotech drugmaker have returned +9.8% over the past month versus the Zacks S&P 500 composite's +4% change. The Zacks Medical - Biomedical and Genetics industry, to which Amgen belongs, has gained 11.9% over this period. Now the key question is: Where could the stock be headed in the near ...

FDA Has Issued New Postmarketing Requirement LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval THOUSAND OAKS, Calif., Dec. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS® (sotorasib). This review, which resulted in a Complete Response Letter, was based on the CodeBreaK 200 ...

Amgen Inc. AMGN, -0.67% said Tuesday that the regulatory review of its supplemental new drug application seeking full approval of Lumakras resulted in a “complete response letter” from the U.S. Food and Drug Administration. A CRL means the application will not be approved in its current form. The biotechnology company said the FDA also issued a new postmarketing requirement of an additional study to support full approval, to be completed no later than February 2028. The NDA for Lumakras was based on result ...

Amgen Inc. (NASDAQ:AMGN) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 9:10 AM ET Company Participants Peter Griffith - EVP and CFO Paul Burton - Chief Medical Officer Justin Claeys - VP, IR Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat It’s pleasure to have Amgen management with us today. I feel like between Sean [ph] and myself covering Amgen for, like, 14 years now, I have not seen this type of setup come up in terms of pipeline readouts for Amgen, in a long time. ...

Q3 ’23 Earnings Call Safe Harbor Statement Thispresentationcontainsforward-lookingstatementsthatarebasedonthecurrentexpectationsandbeliefsofAmgen. Allstatements,otherthanstatementsofhistoricalfact,arestatementsthatcouldbedeemedforward-looking statements,includinganystatementsontheoutcome,benefitsandsynergiesofcollaborations,orpotentialcollaborations,withanyothercompany(includingBeiGene,Ltd.orKyowaKirinCo.,Ltd.),theperformanceofOtezla®(apremilast) (includinganticipatedOtezlasalesgrowthandthetimingofnon-GAAPE ...